It would be better to know more about the patient who received the Remdesivir. A downside of HIPPA healthcare information privacy rules is that they inhibits the transfer of useful information about new therapies. Researchers can't require a patient to waive their privacy rights as a condition of receiving an experimental therapy, but they should ask them to voluntarily do so. Although someone at death's door is in a pretty vulnerable position to be asked to do anything, the greatest good for the greatest number should prevail.